Research Project

Project Title:

Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Immune glomerulopathies

Project Summary:

Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).

Lead principal investigator(s):

Olga Baraldi, Bologna
Gisella Vischini, Bologna

Co-investigator(s):

Anita Campus, Bologna
Beatrice Claudia Marchegiani, Bologna

Project Period:

09/2021   -   12/2025

Sponsors:

Industry

« Back to research page